NCT05148546 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05148546
Title	Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer (NESCIO)
Acronym	NESCIO
Recruitment	Active, not recruiting
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	The Netherlands Cancer Institute
Indications	clear cell renal cell carcinoma
Therapies	Ipilimumab + Nivolumab Nivolumab Nivolumab + Relatlimab
Age Groups:	senior \| adult
Covered Countries	NLD \| GBR

Facility	Status	City	State	Zip	Country	Details
Netherlands Cancer Institute		Amsterdam	North Holland	1066CX	Netherlands	Details
Royal Free London NHS Foundation Trust		London		NW3 2QG	United Kingdom	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT05148546Clinical Trial Detail